Statera Biopharma, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -0.14%333.130.0%$4446.65m
BNTXBioNTech SE 2.34%269.010.0%$740.16m
NVAXNovavax, Inc. -15.79%135.2079.4%$598.80m
AMGNAmgen, Inc. 1.12%209.111.4%$552.47m
SNSSSunesis Pharmaceuticals, Inc. 4.15%6.400.7%$447.38m
REGNRegeneron Pharmaceuticals, Inc. 1.58%560.812.7%$438.38m
GILDGilead Sciences, Inc. -0.02%66.891.0%$413.00m
CCXIChemoCentryx, Inc. 4.46%35.152.9%$402.52m
ILMNIllumina, Inc. -0.30%412.863.3%$373.52m
XLRNAcceleron Pharma, Inc. -0.65%172.625.3%$348.06m
VRTXVertex Pharmaceuticals, Inc. 0.08%185.561.9%$269.98m
BIIBBiogen, Inc. -0.85%265.861.7%$241.47m
OCGNOcugen, Inc. 4.98%8.750.0%$185.31m
XENEXenon Pharmaceuticals, Inc. 2.06%30.430.4%$163.71m
CRSPCRISPR Therapeutics AG -1.66%98.600.6%$159.44m

Company Profile

Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia. The firm is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.